Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Aimmune Therapeutics, Inc.
This is an international, multicenter, open-label, 2-arm follow-on study of the safety, tolerability, and efficacy of AR101 in peanut-allergic individuals who have completed the ARC003 study. This study will explore alternative dosing regimens during extended maintenance with AR101.
Age
4–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Completion of the ARC003 study
Written informed consent and/or assent from subjects/guardians as appropriate
Use of effective birth control by sexually active female subjects of child-bearing potential
You may not be if
Early discontinuation from the ARC003 study
(Group 2 only) Failure to tolerate ≥ 443 mg cumulative of peanut protein with no or mild symptoms in the ARC003 study Exit DBPCFC
Any other condition that, in the opinion of the Investigator, precludes participation for reasons of safety
